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 Summary
Allergic rhinitis is an infl ammatory disease of the nasal mucosa, caused by an IgE-mediated reaction after exposure to the allergen to 
which the patient is sensitized. Histamine is the most important preformed mediator released in the early stage of the allergic reaction, 
and also contributes to the late phase of the latter, exhibiting proinfl ammatory effects.
Minimal persistent infl ammation is a physiopathological phenomenon induced by the presence of an infl ammatory cell infi ltrate, together 
with ICAM-1 expression in the epithelial cells of the mucosa exposed to the allergen to which they are sensitized, in the absence of clinical 
symptoms. This molecule is considered to be an allergic infl ammatory marker.
The priming effect fi rst described by Connell in 1968 consists of the reduction in the allergen concentration required to elicit a nasal 
hyper-response when performing a daily nasal exposure test. This implies that with natural exposure to inhaled allergens, small amounts 
of environmental allergen will maintain the patient symptoms, and thus of course minimal persistent infl ammation.
Considering the above, it is questionable whether antihistamines should be administered on a continuous basis or upon demand.
The antihistamines, and fundamentally the second-generation drugs, have been shown to exert an antiinfl ammatory effect, and this effect 
is greater when the drug is administered continuously than when administered upon demand. Likewise, a reduction in treatment cost and 
an improvement in quality of life among patients treated on a continuous basis has been documented. However, no studies have been 
specifi cally designed to clarify the indication of treatment on a continuous basis or upon demand, as occurs in the GINA. As a result, the 
individualization of treatment according to the concrete characteristics of each patient seems to be the best approach, at least for the 
time being.
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 Resumen
La rinitis alérgica es una enfermedad infl amatoria de la mucosa nasal provocada por una reacción mediada por IgE tras la exposición a 
un alérgeno al que el paciente está sensibilizado. La histamina es el mediador preformado más importante liberado en la fase temprana 
de la reacción alérgica, y también contribuye a la fase tardía de la misma, presentando efectos proinfl amatorios.
La infl amación mínima persistente es un fenómeno fi siopatológico provocado por la presencia de un infi ltrado celular infl amatorio, junto 
a la expresión de ICAM-1 en las células epiteliales de las mucosas expuestas al alérgeno al que están sensibilizadas, en ausencia de 
sintomatología clínica. Se considera un marcador de infl amación alérgica. 
El efecto priming descrito por Connell en 1968 consiste en la reducción de la concentración necesaria de alérgeno para obtener una 
hiperrespuesta nasal si se realiza una prueba de exposición nasal diaria. Esto implica que con una exposición natural a alérgenos 
inhalados, pequeñas cantidades de alérgeno ambiental mantendrán la sintomatología del paciente y, por supuesto, una infl amación 
mínima persistente.
Teniendo en cuenta todo lo anterior es discutible si los antihistamínicos deben ser administrados de forma continua o a demanda.
Los antihistamínicos, prinicipalmente los de segunda generación, han demostrado tener un efecto antiinfl amatorio, y que este efecto es 
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Introduction
Allergic rhinitis is an infl ammatory disease of the nasal 
mucosa induced by an IgE-mediated reaction, following 
exposure to an allergen to which the affected patient is 
sensitized. Clinically, the condition manifests as nasal itching 
(pruritus), sneezing, rhinorrhea (runny nose) and congestion. 
The condition is classified as intermittent or persistent, 
depending on the duration of the symptoms, and as mild or 
moderate-severe depending on their intensity [1]. The co-
existence of conjunctival symptoms in the form of eye itching, 
conjunctival injection and lacrimation is common.
Among the different disorders that may be associated to 
allergic rhinitis, mention must be made of bronchial asthma 
(rhinitis being an important risk factor for the development 
of asthma), sinusitis, otitis media, nasosinusal polyposis, 
respiratory infections and alterations in dental occlusion.
The prevalence of allergic rhinitis in the world population 
is high, varying from 10-40% according to the geographical 
setting considered [2]. The disease has a negative impact upon 
quality of life (performance at work and in school, social 
activities) and generates important direct as well as indirect 
economical costs. Allergic rhinitis is an important public 
health problem. However, despite the above considerations, 
and because of the apparently mild nature of the disorder, it 
usually does not receive the deserved attention by physicians, 
and in most cases is not treated as required.
The H1 histamine receptor belongs to the family of 
receptors coupled to protein G, and it is characterized by an 
equilibrium between its active and inactive conformations [3]. 
Binding of the histamine molecule to the H1 receptor stabilizes 
the latter in its active conformation. The H1 antihistamines 
(anti-H1 drugs) combine with and stabilize the inactive form 
of the H1 receptor; this mechanism is known as inverse 
agonism. The antihistamines have been divided into fi rst and 
second generation drugs, according to their pharmacokinetic 
properties, structural characteristics and adverse effects.
Histamine from the mast cells and basophils is the most 
important preformed mediator released in the early phase of 
the allergic reaction. Histamine stimulates smooth muscle and 
exerts a vasodepressive effect. Such actions have been known 
for almost a century, though in recent years histamine also has 
been reported to modulate infl ammatory responses. It also 
contributes to the late phase of the allergic reaction, as will be 
seen later on. The use of H1 antihistamines in allergic disease 
was initially designed only to block histamine action, without 
taking into account other parallel actions. It is now known that 
the H1 antihistamines exert effects different from those that 
can be explained on the grounds of H1 block alone. A number 
of second-generation H1 antihistamines have been shown to 
reduce mediator release, infl ammatory cell infi ltration, and 
the expression of adhesion molecules by epithelial cells. 
To summarize, anti-H1 drugs have been shown to exert an 
antiinfl ammatory effect [4].
Attitude towards oral H1 antihistamine 
use in allergic rhinitis, on the part of the 
international consensus guides
Both in the ARIA document [1] and in a recent update to 
the latter [5] on the use of oral antihistamines for the treatment 
of intermittent and persistent allergic rhinitis in both adults and 
children, level A evidence was attributed to such prescription 
(recommendation based on randomized, controlled clinical 
trials or metaanalyses). Thus, the indication of such drugs for 
the treatment of allergic rhinitis is not questionable.
Oral anti-H1 drugs are effective for treating all the 
symptoms of allergic rhinitis, though their effi cacy falls short 
of that of the topical nasal corticoids in providing relief from 
nasal congestion.
Allergic rhinitis and histamine
As has been commented above, allergic rhinitis is an 
infl ammatory disorder of the nasal mucosa in which histamine 
plays a key role. Taking into account the infl ammatory nature 
of the disease, and focusing on histamine - particularly as 
regards its activity upon the late phase of the allergic reaction 
- the following effects have been documented [6]:
- Increased secretion of proinfl ammatory cytokines and 
adhesion molecules.
- Increased allergen-induced eosinophil chemotaxis.
- Increased mast cell chemotaxis.
- Inhibition of neutrophil activation and degranulation.
- Increased angiogenesis within the infl amed tissues, this 
being required for perfusion of the latter and for favoring cell 
arrival within the infl ammatory site, via induction of vascular 
endothelial growth factor (VEGF) [7].
On the basis of the above, it can be affi rmed that histamine 
exerts much more complex functions than initially believed, 
and moreover exerts proinfl ammatory action.
mayor si la administración del fármaco se realiza de forma continua que si se realiza a demanda. Así mismo se ha objetivado una reducción 
de costes del tratamiento y una mejora de la calidad de vida de los pacientes que han recibido el tratamiento de forma continua. Pero no 
existen estudios específi camente diseñados para clarifi car la indicación del tratamiento continuo o a demanda como ocurre con la GINA, por 
lo que individualizar el tratamiento de acuerdo con las características del paciente parece, por el momento, la mejor postura a seguir.
Palabras clave: Rinitis alérgica. Antihistamínicos. Infl amación mínima persistente. Efecto priming. Tratamiento continuo. Tratamiento a 
demanda.
Allergic rhinitis: Continuous or on demand antihistamine therapy?
 J Investig Allergol Clin Immunol 2007; Vol. 17, Suppl. 2: 21-27© 2007 Esmon Publicidad
23
Minimal persistent infl ammation and 
the priming effect: two phenomena to 
be taken into account
a) Minimal persistent infl ammation (MPI)
Minimal persistent infl ammation is a physiopathological 
phenomenon referring to the presence of an infl ammatory 
cell infi ltrate (eosinophils, neutrophils) associated with the 
expression of intercellular adhesion molecule-1 (ICAM-1 / 
CD-54) in the epithelial cells of the mucosa exposed to the 
allergen, in the absence of clinical symptoms.
MPI was initially described for bronchial asthma [8], 
though posteriorly it was also described in relation to allergic 
rhinitis secondary to hypersensitivity to dust mites [9], where 
patients without symptoms but permanently exposed to the 
acarids (mites) presented nasal mucosal infl ammation. It 
was considered a marker of allergic infl ammation [10], since 
ICAM-1 is only expressed in the mucosal epithelial cells of 
allergic patients when they are in contact with the allergen 
- but not in non-allergic patients, or allergic patients when 
not exposed to the allergen [11,12]. ICAM-1 belongs to the 
immunoglobulin superfamily, and is constitutively expressed 
by T and B lymphocytes, monocytes and fi broblasts. A very 
important characteristic of ICAM-1 is that it is the epithelial 
cell receptor for over 90% of all rhinoviruses, which bind to 
the receptor in order to penetrate and infect the cell. Once 
within the cell, the rhinoviruses increase ICAM-1 expression 
at the epithelial cell surface, thereby favoring the penetration 
of more rhinoviruses [13].
b) The priming effect
The term “priming effect” was introduced by Conell in 1968. 
While conducting nasal exposure tests with Ambrosia pollen, he 
found that with daily provocation, less pollen was needed (between 
10 and 100 times lesser amounts of allergen) to elicit the same 
response, i.e., hyper-responsiveness developed. Approximately 
one week without provocation was required in order for this effect 
to disappear. This means that if an allergic patient is permanently 
exposed to the allergen to which he or she is sensitized, then the 
presence of the allergen even at low concentrations will suffi ce 
to induce a persistent nasal infl ammatory phenomenon that will 
exacerbate with only minimal increments in the usual exposure 
to the causal allergen.
c) Why are both these phenomena important?
On one hand, permanent exposure to small amounts of 
an allergen to which the patient is sensitized increases nasal 
hyper-responsiveness, i.e., in practical terms the persistent 
inhalation of a small amount of allergen induces evident 
symptoms. Under natural conditions, exposure to inhaled 
allergens - particularly those that are perennial and with the 
greatest seasonal variability according to the geographical 
setting involved - shows a similar tendency. This means that 
although the patient may attempt to minimize exposure, he 
or she always will be exposed to small amounts of allergen 
that maintain the symptoms. No massive exposure is required 
for this to occur (though massive exposure may occasionally 
take place).
On the other hand, the persistence of allergen exposure 
favors the presence of MPI - which in turn also favors nasal 
hyper-responsiveness, with the consequences stated above. 
Patients sensitized to pollen have been reported to show nasal 
hyper-responsiveness to methacholine outside the pollination 
season [14]. Furthermore, however, the presence of ICAM-1 
expression increases the co-morbidity of rhinitis, as has been 
described in a number of articles, favoring the presence of 
upper airways infections and the subsequent deterioration of 
the quality of life of these individuals [15].
The antiinfl ammatory effect of 
antihistamines
As has been commented above, histamine exerts potent 
proinfl ammatory action, and antihistamines could possess 
different effects within the complex network of infl ammatory 
reactions of an allergic nature.
Inverse agonism per se does not explain anti-H1 drug 
action upon the adhesion molecules, upon cell migration 
towards the site of inflammation, or upon the inhibition 
of proinflammatory cytokine production. In fact, these 
antiinfl ammatory effects are inherent to the second-generation 
H1 antihistamines, and are not seen in the case of the fi rst-
generation drugs [4,16] - though both generations interact 
equally with the H1 receptor. Nevertheless, a recent study has 
reported inhibition of infl ammatory mediator expression with 
chlorpheniramine [17].
Histamine, though a series of biochemical steps, activates 
protein kinase C (PKC). PKC in turn activates both ERK (a 
subfamily of mitogen-activated protein kinases, or MAPKs) 
and nuclear factor κB (NF-κB).
ERK is associated with the production of anti-apoptotic, 
differentiation and genic expression phenomena (e.g., cytokine 
expression), and with cell growth and proliferation regulatory 
processes (e.g., infl ammatory cells) [18]. 
NF-κB is a cytoplasmic transcription factor which 
after activation penetrates the cell nucleus and binds to 
promoter regions of genes that regulate the synthesis 
of adhesion molecules, chemokines, proinflammatory 
cytokines, cyclooxygenase-2 (Cox-2) inducible nitric oxide 
synthase (iNOS). NF-κB is activated in those locations 
where infl ammation is found in different disease processes 
(rheumatoid arthritis, multiple sclerosis, chronic demyelinating 
infl ammatory polyneuropathy, allergic rhinitis and asthma, 
inflammatory bowel disease, arteriosclerosis, gastritis 
associated to H. pylori, and systemic infl ammatory response 
syndrome, or SIRS) [19]. 
Down-regulation of NF- κB is the most likely mechanism 
by which anti-H1 drugs develop their antiinfl ammatory effects. 
In parallel, such down-regulation reduces the expression of 
proinfl ammatory cytokines. Nevertheless, the antihistamines 
also have been reported to exert other effects that can be 
classifi ed as antiinfl ammatory, such as the inhibition of free 
oxygen radical production by alveolar macrophages via 
interaction with PKC [20]; the inhibition of NADPH oxidase 
[21]; the inhibition of angiogenesis via VEGF reduction [22]; 
or the reduction of granulocyte-macrophage colony stimulating 
factor (GM-CSF) release by the epithelial cells of the nasal 
mucosa, associated to secondary reduction in the number of 
eosinophils and their survival [23].
J Montoro, et al
J Investig Allergol Clin Immunol 2007; Vol. 17, Suppl. 2: 21-27 © 2007 Esmon Publicidad
24
Reductions in ICAM-1 levels have been reported with 
oxatomide [24], cetirizine [25], terfenadine [26], azelastine 
[27], loratadine [28], desloratadine [29] and mizolastine [30]. 
Likewise, reductions in VCAM (vascular cellular adhesion 
molecule) have been observed with levocetirizine [31], as well 
as decreased platelet activating factor (PAF) with rupatadine 
[32], and lowered inflammatory cell counts (neutrophils, 
eosinophils) among allergic patients after receiving different 
anti-H1 treatments. Furthermore, such reductions are seen to be 
greater in patients receiving continuous treatment than in those 
using the medication upon demand [8-11, 33-36]. Dizdar et al. 
[37] found that total IgE and bronchial hyper-responsiveness did 
not increase during the pollination period in patients with allergy 
to grass pollen treated with desloratadine on a continuous basis 
- though both parameters increased signifi cantly among those 
subjects receiving treatment upon demand. 
In sum, it can be affi rmed that the antihistamines exert an 
antiinfl ammatory effect, and that this effect is greater when 
the medication is administered continuously.
The effect of antihistamines upon 
symptoms control and quality of life
The symptoms of allergic rhinitis reduce patient quality 
of life (both children and adults), as a result of the physical 
and emotional disturbances, diminished performance at work 
and/or school, and sleep disturbances. Patients with persistent 
rhinitis suffer more symptoms, and these are moreover more 
severe, and require more symptomatic treatment than patients 
with intermittent rhinitis [38].
Different questionnaires have been used to assess quality 
of life among patients with allergic rhinitis, including the 
RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire), 
the SF-36 (Short-form 36 Health Status Questionnaire) 
[39,40], Rhinasthma (a specifi c questionnaire for patients 
with rhinitis and/or asthma) [41], and the SPRINT (recently 
used and validated in the Spanish population). The TSS (Total 
Symptom Score) is used in most studies to record the sum of 
the intensity of symptoms (nose and eye itching, sneezing, 
runny nose, nose congestion or stuffi ness), on a scale from 
0-3. Of the typical symptoms of rhinoconjunctivitis, the most 
bothersome for the patient and the most resistant to anti-H1 
treatment is nasal congestion. In this context, a criterion of 
optimum effi cacy for the new antihistamines is their effi cacy 
also against congestion [5].
The XPERT study [42] evaluated not only quality of life 
and the reduction in patient symptoms score, but also the 
reduction in direct and indirect costs associated with treatment, 
in patients with persistent rhinitis continuously treated with 5 
mg a day of levocetirizine. Quality of life and the TSS both 
showed signifi cant improvement after the fi rst week of therapy, 
nose congestion decreased signifi cantly after fi ve weeks of 
treatment [43], and both the disorders associated to rhinitis 
and the global (direct and indirect) costs decreased. The 
study mentions that the MPI found in patients with persistent 
rhinitis can reduce their quality of life and social productivity 
- continuous treatment with levocetirizine being indicated in 
such situations.
Likewise, Ciprandi et al. [44] in children showed 
continuous cetirizine during 6 months to signifi cantly reduce 
the symptoms of asthma and rhinitis, the need for additional 
medication, and the global cost of therapy.
The effect of the different second-generation antihistamines 
in terms of symptoms reduction in both perennial and seasonal 
rhinitis has been demonstrated by a series of studies [45-49].
Particular situations in which MPI 
theoretically should be present
a) Polysensitized patients
Polysensitized patients are commonly seen in allergy 
clinics (31.2%) [50]. They are naturally exposed to a larger 
number of aeroallergens during long periods of the year, or 
even all year long, depending on the geographical setting 
involved.
If such patients present persistent symptoms, and 
fundamentally in the case of those with sensitization to both 
types of allergen (perennial and seasonal), then the need for 
continuous treatment in order to improve symptoms and quality 
of life becomes evident.
Ciprandi et al. [51] showed that continuous long-term 
treatment (3 years) with 10 mg of cetirizine a day in children 
monosensitized to dust mites and with manifestations of 
persistent rhinitis and/or intermittent mild asthma reduced the 
incidence of new sensitizations to aeroallergens, with respect 
to those receiving cetirizine upon demand.
b) Occupational / personal exposure to the allergen
Patients with occupational respiratory allergic disease are 
exposed to allergen action in their working environment, and 
for the full duration of the work shift. The measures adopted 
to avoid exposure are often insuffi cient in themselves, either 
because they are bothersome (e.g., the wearing of face masks) 
and are therefore not used, or because they are not effective 
and exposure - while lessened to some extent - is thus still 
suffi cient to perpetuate the symptoms. 
Another situation is represented by patients exposed to the 
allergen daily in their normal life (e.g., people with domestic 
pets who suffer allergy to animal epithelia). Continuous 
exposure generates persistent symptoms.
c) Perennial allergens
Exposure to perennial allergens is variable in terms of 
duration and allergenic range, depending on the geographical 
setting. In the case of dust mites (the most common perennial 
allergen source), certain temperature and humidity conditions 
are required (about 23ºC and 75% relative humidity) for 
allergen number (and thus also exposure) to increase.
However, and despite the term “perennial”, in many areas 
such allergens actually show seasonal variations (spring and 
autumn), fundamentally in areas of the Spanish Mediterranean 
coast, and of greater intensity if the patients are also sensitized 
to pollen [52]. For this reason, patients sensitized to perennial 
allergens can manifest intermittent symptoms [53].
d) Exposure to pollen with prolonged pollination periods
There is great variability in the pollinic range in Spain, 
depending on the geographical setting. Such variability does 
not refer only to the different majority pollens found in each 
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zone, or to the total pollen grains per cubic meter reached in 
each area, but also to the duration of the pollination periods 
- these moreover experiencing changes with the climatic 
conditions. 
Thus, in areas with very mild spring and autumn seasons, as 
on the Spanish Mediterranean coast, species such as Parietaria 
extend their pollination period from February to June, with an 
additional peak from August to October - thus ensuring the 
maintenance of symptoms for almost the entire year.
e) Environmental pollution
As has been extensively commented in other articles 
of this same number, environmental pollution with diesel 
exhaust particles acts upon the healthy individual, increasing 
the presence of infl ammatory cells in the airways, and the 
levels of histamine, cytokines (IL-6, IL-8), adhesion molecules 
(ICAM-1 and VCAM-1), neutrophils and platelets in the 
bloodstream. Such situations can lead to a type Th1- or Th2-
mediated infl ammatory response [54]. Ozone in turn exerts an 
oxidizing effect and irritates the airways. Exposure to nitrogen 
oxide (NO
2
) can induce an airways infl ammatory response and 
may favor sensitization to aeroallergens [55]. Environmental 
pollution also increases pollen allergenicity [56] and favors 
pollen presence, vehiculized by means of minute particles, 
during periods of the year that do not correspond to the natural 
pollination period [57]. Exposure to environmental pollution 
thus becomes another condition to be taken into account in 
patients with allergy to perennial and/or seasonal allergens, as 
a factor causing or favoring the persistence of symptoms.
Conclusions
Although many studies can be found in the literature on 
antihistamine use, symptoms control in patients with allergic 
rhinitis, and treatment cost, there is currently no evidence to 
indicate whether anti-H1 drug use on a continuous basis is 
better than treatment on demand.
Although the ARIA study [1] and the opinions of experts 
advise continuous treatment to control MPI and prevent the 
appearance of symptoms [58], other sources question the 
studies made in relation to the antiinfl ammatory effect of H1 
antihistamines, citing the lack of uniformity in the models used, 
and placing in doubt the in vivo relevance of the results obtained 
in vitro [59,60]. In any case, the results of the XPERT [41] and 
ETAC studies (prevention of asthma in children sensitized to 
dust mites or grass, with atopic dermatitis treated on a daily 
basis with cetirizine during 18 months) [61] are favorable to 
the continuous use of anti-H1 medication. On the other hand, 
it is clear that the second-generation H1 antihistamines offer 
a good clinical and safety profi le [62-66]; daily dosing, if 
required, is therefore not unreasonable.
The most reasonable approach thus appears to be the 
individualization of treatment according to the characteristics 
of each patient, and administration of the medication on a 
continuous basis or upon demand - taking into account the 
specifi c conditions involved (type of sensitization, continuous 
or discontinuous exposure, and geographical setting). 
Undoubtedly, further studies are needed, specifi cally designed 
to answer this question and to establish a management protocol 
similar to that of the GINA, which points to the convenience 
of treating not only what we see (symptoms) but also what we 
do not see but know to be there (MPI).
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